Tectonic reports Phase 1a safety data for TX2100 in HHT program
The company also disclosed FDA Fast Track designation and IND clearance for TX2100, its APJ receptor antagonist for hereditary hemorrhagic telangiectasia.
SEC filing
Latest
2 stories
Tuesday, September 29
Thursday, August 6
Tectonic completes APEX enrollment for TX45 in PH-HFpEF, IDMC backs continuation
Tectonic Therapeutic finished enrolling its Phase 2 APEX trial and cleared a July safety review, with topline data still expected in early Q1 2027.
SEC filing